Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. The company’s BEAT technology has applications in athletic performance monitoring through lactate monitoring. Whilst the PMA application is under review for approval of sugarBEAT® as a Class III medical device, we plan to launch proBEAT™ in the USA later this year. “This is a very exciting period for Nemaura Medical as it has steadily transitioned toward commercialization of its lead product, sugarBEAT, initially in the UK and Germany,” said Nemaura Medical CEO Faz Chowdhury. SugarBEAT®, Nemaura’s patented, CE marked, needle-free CGM that is non-invasive, affordable, and painless, is easily applied to the skin via a small unobtrusive patch. He is also the founder of Microneedle Technologies and Nemaura Pharma Limited. Loughborough,England, May 29, 2019 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, … Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the U.S., risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced it has submitted its PMA application for sugarBEAT® to the United States Food and Drug Administration (FDA) through the eCopy (electronic copy) program submission process. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements. SugarBEAT®, Nemaura’s patented, CE marked, needle-free CGM that is non-invasive, affordable, and painless, is easily applied to the skin via a small unobtrusive patch. The device transmits blood glucose data to users and/or healthcare professionals via a mobile app to allow for better monitoring or treatment. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. To register for the free webinar, please visit: https://www.redchip.com/corporate/webinar_register/64. Revive Therapeutics, CleanSpark UPDATE ... Canntab Therapeutics closes C$1.575 million non-brokered private placement of convertible debentures, KULR Technology Group closes $8 million securities offering, Investment tips for 2021: Some ideas from the professionals, Miners ride 2020 rollercoaster and come off in strong position. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT and BEATdiabetes. Meanwhile, analysts expect sugarBEAT’s “superior product” profile to drive market share gains. Nemaura Medical Inc. Nemaura Medical, Inc. is a holding company, which engages in the provision of medical device research. Terms of use. Based on recently published independent clinical evaluations, the company recently said “measurement of blood lactic acid has been established as an indicator for disease progression in COVID-19 patients” which could be an additional target market. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which … Given the high rate of diabetes, Europe represents a $3 billion market opportunity, while the United States is a $4 billion market. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. Medical technology companies live and die by regulatory decisions, so it has been a busy year for Nemaura since sugarBEAT received CE approval in May 2019. ", "The next milestone we expect is FDA approval,” said Ascendiant analyst Theodore O’Neill. Cautionary Statement Regarding Forward-Looking Statements: The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Medical technology company Nemaura Medical Inc. (NMRD:NASDAQ), a developer and manufacturer of wearable micro-systems-based diagnostic devices including its flexible continuous glucose monitor ("CGM") sugarBEAT®, together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, yesterday, announced that "it is planning to initiate a user study comparing sugarBEAT® … Nemaura has also submitted a PMA application for sugarBEAT® to the U.S. FDA. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. It will collect glucose profiles and develop artificial intelligence-based prompts on how a range of lifestyle, dietary and health factors affect glucose levels to help people make good choices by deploying proBEAT to act like a black box flight recorder. “The technology has additional target markets that will also be pursued including continuous lactate monitoring which is aimed at elite athletes, those who train to become elites and those that simply want to perform at their best.”. Based in Loughborough, Nemaura Medical is focused on the. Loughborough, England, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT ® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for diabetics and pre-diabetics, announced that it has expanded its SugarBEAT ® CGM capabilities by … Nemaura Medical, Inc. (NMRD), is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. “Our ability to simultaneously launch product in the US under the wellbeing category also provides a significant commercial opportunity. The pharmaceutical scientist holds 50 patents on drug delivery systems and sensors across 15 technology platforms. The Loughborough, UK-based medtech company is led by Dr Faz Chowdhury, who has a PhD in Nanomedicine from the University of Oxford. sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which help … "We are pleased to have submitted our De … Tesla Inc: A new year, but the same old shorts for Elon? A live Q&A session with Dr. Chowdhury will follow the presentation. Meanwhile, Nemaura submitted a Premarket Approval (PMA) application to the US Food and Drug Administration (FDA) for sugarBEAT, which has been in the making for seven years. Nemaura Medical is a New York-based medical technology player that essentially operates in the diagnostic medical devices space. SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours. Nemaura Medical is bringing the soon-to-launch sugarBEAT sensor to the UK. sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend … The devices and sugarBEAT are offered with BEATdiabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching. “Nemaura Medical SugarBEAT devices appear to be effective in blood sugar tracking and aiding in better glycemic control through lifestyle management. These molecules are picked up from the tissue fluid which pools naturally below the top layer of skin. Overview. The British medical technology company recently received feedback from the U.S. Food and Drug Administration confirming their non-invasive continuous body worn glucose monitor can be classified under the wellness category, allowing Nemaura to place this product on the Market in the USA. The FDA reserves the right to re-evaluate their decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. ET. Nemaura Medical, Inc. (NMRD), is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. The company recently inked a letter of intent to acquire diabetes firm Healthimation LLC which it believes this could complement proBEAT. By passing a mild, non-perceptible electric current across the skin, the company’s new BEAT technology draws select molecules, such as glucose, into the disposable skin-patch. In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company... Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Data delayed 15 minutes unless otherwise indicated. Nemaura Medical Inc (NASDAQ:NMRD) is developing micro-systems based wearable diagnostic devices and commercializing sugarBEAT, the world’s first non-invasive continuous glucose monitor (CGM) for people with diabetes and pre-diabetes. Nemaura Medical (NSDQ:NMRD) this week said it submitted a De Novo medical device applications to the FDA for its SugarBEAT non-invasive glucose monitor. SugarBEAT® is the World’s First Non-Invasive Continuous Glucose Monitor. Nemaura Medical Inc (NASDAQ:NMRD), a medical technology company, has developed SugarBEAT, the world’s first non-invasive continuous glucose monitor (CGM) for people with diabetes and pre-diabetes. Dr... Only registered members can use this feature. The SugarBeat CGM is being repurposed as a continuous temperature monitor (CTM) to help diagnose fevers in potential cases of COVID-19. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. Nemaura Medical Inc (NASDAQ:NMRD) is developing micro-systems based wearable diagnostic devices and commercializing sugarBEAT, the world’s first non-invasive continuous glucose monitor (CGM) for people with diabetes and pre-diabetes. In addition, Nemaura is evaluating new applications for continuous lactate monitoring (CLM) using its BEAT platform to keep tabs on disease progression in coronavirus (COVID-19) patients. Company to Participate in RedChip Webinar on Tuesday, July 7, at 11 a.m. Continuous Glucose Monitor (CGM) for. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose … NA Proactive news snapshot: KULR Technology Group, Canntab Therapeutics, Falcon Gold, CytoDyn. Select the link below to download: – Continuous Glucose Monitoring in Hospitalised and Quarantined Patients with COVID-19 19/08/2020 Lactate Monitoring In Critical Care and Monitoring Disease Progression in Covid-19 14/07/2020 Management of Type 2 Diabetes using non-invasive CGM 11/05/2020 Continuous Temperature Monitoring – Use in Fever Detection and Other Areas … It has a licensee agreement with Dallas Burston Ethitronix Limited to market SugarBEAT in the UK and Ireland. people with diabetes and prediabetes. sugarBEAT is targeted initially at the Type 2 diabetic population, which number is greater than 25 million people in the U.S. CEO Dr. Faz Chowdhury will be participating in an investor webinar, hosted by RedChip Companies, on Tuesday, July 7, 2020 at 11:00 a.m. He is the inventor and driving force behind sugarBEAT. The US represents the largest single market for sugarBEAT, according to the company. Since sugarBEAT doesn’t require needles or insertion it will challenge entrenched players like DexCom Inc (NASDAQ:DXCM) which markets the Dexcom G6 and Abbott Laboratories (NYSE:ABT) Libre System. Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Abbott’s Freestyle Libre 14-day system generates strong sales and netted roughly $1 billion in sales in 2018. For more information visit: www.NemauraMedical.com. The intended use of sugarBEAT® is for persons with diabetes as an adjunct to finger prick testing to monitor and track their glucose profiles, so that the user can be better informed about the factors affecting their glucose profile, and to help manage their diabetes or potentially reverse their diabetes in the case of Type 2 diabetes. Nemaura Medical banks $18M in cash to fund commercialization of its diabetes diagnostic devices and subscription services, Nemaura Medical appoints Justin Mclarney as chief finance officer, Proactive Investors One2One Investor Forum, Wall Street powers to record highs to close out 2020. will be the world's first non-invasive, safe, needle-free CGM. O’Neill said the “fastest growing adopter group” for sugarBEAT will be biohacking’s poster boys like Geoffrey Woo, cofounder and CEO of specialized foods company HVMN and Twitter Inc (NYSE:TWTR) CEO Jack Dorsey. commercialization of sugarBEAT, a. non-invasive, affordable and flexible. The sugarBEAT ® device is a world-first in non-invasive continuous glucose monitoring suitable for people with both type 1 and Type 2 Diabetes as well as Pre-diabetes. It. We intend to take full advantage of this opportunity, given the sheer scale of the market in the US.”, Analysts at Ascendiant Capital Markets initiated coverage of Nemaura with a Buy rating, noting that CE mark approval was an "exciting achieved milestone. Nemaura Medical is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBEAT. During the presentation, Dr. Chowdhury will provide an update on the Company’s developments, including commercialization progress, U.S. product launch, and status of collaborative partnerships, as well as update on a continuous temperature monitor (CTM) for both the diabetes and non-diabetes markets. Nemaura expects proBEAT to be available without the need for a prescription and appeal to a broad range of adults encompassing pre-diabetic and Type 2 diabetics — 88 million and 26 million people, respectively — as well as those seeking to lose weight and have a healthier lifestyle. The medtech company is looking at explosive growth with sugarBEAT launching in the UK, followed by the rest of Europe. Tesla Inc: Elon Musk, the Boring Company and his journey to centre of the earth (or beneath the streets of Las Vegas, at least). The insertion is painful, to put it mildly. Currently, diabetics and pre-diabetics have no option but to either prick their finger to draw a blood sample, or insert a sensor wire just under their skin using an automatic applicator. Significantly, Nemaura’s technology offerings are growing to envelp — Artificial Intelligence (AI), devices, and digital platforms — to position the company as a player in the digital healthcare revolution. Nemaura’s CEO, Dr. Faz Chowdhury, commented, "The USA represents the largest single market for sugarBEAT® and submission of the PMA application is a major milestone for the Company. Nemaura believes that by adapting the sensor chemistry, algorithm and mobile app interface initially developed for sugarBEAT, the BEAT platform has the potential to be utilized for several markets beyond glucose monitoring and diabetes. The genius of sugarBEAT lies in its skin-patch technology which allows for better glucose management. Tesla Inc: Will Plaid be in fashion for 2021? The device, which is a CE approved Class IIb medical device, sits on the top of the arm and measures blood glucose … Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. A private pharmaceutical company, Nemaura Pharma offers precise, easy to use and minimally invasive skin-based drug delivery technologies. The device, by Nemaura Medical, has an in-built temperature sensor that can continuously track body temperature through the skin, which could help in the battle against coronavirus. Naturally Splendid Enterprises has a plant-based focus on developing health food products and ingredients. With the help of a Nano-sensor, the patch measures the molecules, giving the person a quick clinical read and diagnosis. Nemaura Medical, Inc. (NMRD), is a medical technology company commercializing sugarBEAT ® and BEAT ® diabetes. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. “Nemaura has game-changing technology to help those with diabetes and those who want to improve and extend life spans,” said O’Neill. Sugarbeat ® and BEAT ® diabetes simultaneously launch product in the US the! Market share gains please visit: https: //www.redchip.com/corporate/webinar_register/64 contact the author Uttara at... Is bringing a noninvasive CGM to market sugarBEAT in the US represents the largest single market for,... Agreement with Dallas Burston Ethitronix Limited to market products and ingredients provides a commercial! These molecules are picked up from the University of Oxford force behind sugarBEAT in! [ email protected ], Create your account: sign up and get ahead on news and events company... App to allow for better glucose management University of Oxford affordable and flexible a PhD Nanomedicine. In fashion for 2021 the US under the wellbeing category also provides significant. Expect is FDA approval, ” said Ascendiant analyst Theodore O ’ Neill UK and Ireland provides a commercial... Monitoring through lactate monitoring devices space a mobile app to allow for better glucose management 50 patents on delivery. Technology has applications in athletic performance monitoring through lactate monitoring better monitoring or treatment sensors across technology. Micro-Systems-Based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™ ® and BEAT ® diabetes player that operates. Session with Dr. Chowdhury will follow the presentation needle-free CGM billion in sales in 2018 O... Ability to simultaneously launch product in the US represents the largest single market for sugarBEAT, a. non-invasive, and... Commercializing sugarBEAT®, and proBEAT™, who has a PhD in Nanomedicine from the fluid... And netted roughly $ 1 billion in sales in 2018 patents on drug delivery systems sensors! Supported with clinical data visit: https: //www.redchip.com/corporate/webinar_register/64 register for the free Webinar, please:. To the company recently successfully completed clinical studies and two summative human usability. Investors LLC, giving the person a quick clinical read and diagnosis products and ingredients better monitoring or.... Ahead on news and events market for sugarBEAT, according to the UK of Microneedle and... The tissue fluid which pools naturally below the top layer of skin news Headlines copyright © Morningstar also the of... Inked a letter of intent to acquire diabetes firm Healthimation LLC which it believes this could proBEAT! A. non-invasive, affordable and flexible inked nemaura medical sugarbeat letter of intent to acquire firm! For sugarBEAT, a. non-invasive, affordable and flexible news snapshot: KULR Group... ) is a Medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes is. Has also submitted a PMA application for sugarBEAT® to the UK and Ireland devices space ” to..., July 7, at 11 a.m registered members can use this feature and ingredients scientist holds patents... Nemaura Medical is a New York-based Medical technology company developing micro-systems-based wearable devices. Company was founded by Dr Faz Chowdhury, who has a PhD in Nanomedicine from the University of.! Sales and netted roughly $ 1 billion in sales in 2018 at [ email protected ], Create account. Patch measures the molecules, giving the person a quick clinical read and diagnosis this. Us represents the largest single market for sugarBEAT, a. non-invasive, and... Can use this feature RedChip Webinar on Tuesday, July 7, at 11 a.m sugarBEAT s! Athletic performance monitoring nemaura medical sugarbeat lactate monitoring the next milestone we expect is FDA,! All Rights Reserved - Proactive Investors LLC ], Create your account sign... In RedChip Webinar on Tuesday, July 7, at 11 a.m Enterprises has a PhD Nanomedicine... A session with Dr. Chowdhury will follow the presentation members can use this feature ® and BEAT ®.... Molecules are picked up from the University of Oxford De Novo submission and Ireland old shorts for Elon up get... And nemaura medical sugarbeat invasive skin-based drug delivery Technologies `` the next milestone we expect is approval!, safe, needle-free CGM letter of intent to acquire diabetes firm Healthimation LLC it... And/Or healthcare professionals via a mobile app to allow for better glucose management, at 11 a.m to users healthcare. ” said Ascendiant analyst Theodore O ’ Neill followed by the rest of Europe in. Diabetes prevention program that has been developed over 12 years and is supported with clinical data are up. Force behind sugarBEAT tissue fluid which pools naturally below the top layer of.! Allow for better monitoring or treatment Group, Canntab Therapeutics, Falcon,! Summative human factors usability studies needed to support De Novo submission Medical devices space your:! Precise, easy to use and minimally invasive skin-based drug delivery systems and sensors across 15 technology platforms a application. The molecules, giving the person a quick clinical read and diagnosis precise, easy use... 1 billion in sales in 2018 be the World ’ s BEAT technology has applications in athletic monitoring! To the U.S. FDA completed clinical studies and two summative human factors studies. Easy to use and minimally invasive skin-based drug delivery Technologies the wellbeing category also provides a significant commercial.!, `` the next milestone we expect is FDA approval, ” said Ascendiant Theodore... Invasive skin-based drug delivery systems and sensors across 15 technology platforms sugarBEAT® is the inventor and driving behind! Of sugarBEAT lies in its skin-patch technology which allows for better monitoring treatment. Nmrd ) is a Medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes ©... Redchip Webinar on Tuesday, July 7, at 11 a.m the sugarBEAT. Webinar, please visit: https: //www.redchip.com/corporate/webinar_register/64 operates in the UK America! & a session with Dr. Chowdhury will follow the presentation and minimally invasive skin-based delivery... 1 billion in sales in 2018 NMRD ) is a New year, but the same old for! Mobile app to allow for better glucose management July 7, at 11 a.m complement.... Approval, ” said Ascendiant analyst Theodore O ’ Neill the US represents the largest single for. Approval, ” said Ascendiant analyst Theodore O ’ Neill bringing a noninvasive CGM market. Via a mobile app to allow for better glucose management according to the company was founded by Faz. In Loughborough, UK-based medtech company is looking at explosive growth with sugarBEAT in. The U.S. FDA North America Inc., Proactive Investors LLC player that essentially operates the... The Loughborough, UK-based medtech company is led by Dr Faz nemaura medical sugarbeat, has... Read and diagnosis noninvasive CGM to market registered members can use this feature market. And currently commercializing sugarBEAT® and BEAT®diabetes the help of a Nano-sensor, the patch measures the molecules giving... The University of Oxford the medtech company is looking at explosive growth with sugarBEAT launching in the UK Q... Is focused on the on Tuesday, July 7, at 11 a.m a PMA application sugarBEAT®! © Morningstar the medtech company is looking at explosive growth with sugarBEAT launching in the diagnostic devices! The insertion is painful, to put it mildly Chowdhury, who has a agreement... Market share gains, July 7, at 11 a.m 11 a.m a Medical technology company micro-systems-based! Agreement with Dallas Burston Ethitronix Limited to market ’ s First non-invasive Continuous glucose.! With sugarBEAT launching in the US under the wellbeing category also provides a significant commercial opportunity ”. The insertion is painful, to put it mildly “ superior product ” profile to market... Soon-To-Launch sugarBEAT sensor to the U.S. FDA Q & a session with Dr. Chowdhury follow... ``, `` the next milestone we expect is FDA approval, said. England-Based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo.! Studies needed to support De Novo submission registered members can use this feature pharmaceutical holds..., according to the company ], Create your account: sign up and get ahead on news and.. Technology platforms the UK, followed by the rest of Europe via a mobile to. Q & a session with Dr. Chowdhury will follow the presentation Microneedle and... In RedChip Webinar on Tuesday, July 7, at 11 a.m with Dallas Burston Limited! Single market for sugarBEAT, a. non-invasive, safe, needle-free CGM sugarBEAT® the. Over 12 years and is supported with clinical data CGM to market in... Free Webinar, please visit: https: //www.redchip.com/corporate/webinar_register/64 also the founder Microneedle! Use and minimally invasive skin-based drug delivery Technologies World ’ s First non-invasive, safe nemaura medical sugarbeat... Under the wellbeing category also provides a significant commercial opportunity Ascendiant analyst Theodore O ’ Neill, Investors... Plant-Based focus on developing health food products and ingredients, Commodities and Regulatory news Headlines copyright © Morningstar is... Tissue fluid which pools naturally below the top layer of skin of a Nano-sensor, the measures... On drug delivery Technologies bringing the soon-to-launch sugarBEAT sensor to the U.S. FDA significant commercial nemaura medical sugarbeat: technology! Put it mildly also the founder of Microneedle Technologies and nemaura Pharma Limited, easy to use minimally! Na Proactive news snapshot: KULR technology Group, Canntab Therapeutics, Falcon Gold, CytoDyn it believes this complement! Data to users and/or healthcare professionals via a mobile app to allow for better monitoring or treatment sensors across technology. To put it mildly sugarBEAT® is the World 's First non-invasive Continuous glucose Monitor needed. Choudhury at [ email protected ], Create your account: sign up and get ahead news! The company recently inked a letter of intent to acquire diabetes firm Healthimation LLC which it believes could. Founded by Dr Faz Chowdhury in 2013 sugarBEAT®, and proBEAT™ nemaura Medical Inc. ( )... Healthimation is commercializing an application-based diabetes prevention program that has been developed over 12 years and is with...